Published in Anticancer Res on April 03, 2008
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol (2013) 1.17
Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des (2012) 1.00
The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol (2010) 1.00
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer (2016) 0.90
Immunotherapy for gastrointestinal malignancies. Cancer Control (2013) 0.90
Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J Transl Med (2014) 0.88
Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases. Ann Surg Oncol (2011) 0.85
MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. Biomed Res Int (2012) 0.84
What is recent in pancreatic cancer immunotherapy? Biomed Res Int (2012) 0.84
Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy. Clin Dev Immunol (2010) 0.81
Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Clin Exp Immunol (2010) 0.80
T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology. Clin Dev Immunol (2011) 0.80
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology (2015) 0.78
Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y) (2011) 0.78
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin J Cancer Res (2015) 0.78
MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. PLoS One (2016) 0.77
Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surg Today (2010) 0.76
Immunotherapy for patients with advanced pancreatic carcinoma: A promising treatment. Oncotarget (2016) 0.75
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer (2016) 0.75
Peptides and peptidomimetics as immunomodulators. Immunotherapy (2014) 0.75
Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Immunol Res (2017) 0.75
Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol (2016) 0.75
Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes. Biomolecules (2016) 0.75
Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer. Oncoimmunology (2013) 0.75
Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Pancreas (2017) 0.75
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet (2003) 3.93
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res (2008) 1.64
Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res (2002) 1.64
Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol (2006) 1.62
Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res (2005) 1.58
Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer (2003) 1.51
A new type of protein chip to detect hepatocellular carcinoma-related autoimmune antibodies in the sera of hepatitis C virus-positive patients. Proteome Sci (2013) 1.44
Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One (2012) 1.35
The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology (2005) 1.30
Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia (2008) 1.28
Dual effects of acupuncture on gastric motility in conscious rats. Am J Physiol Regul Integr Comp Physiol (2003) 1.27
MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One (2013) 1.27
Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol (2008) 1.26
MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res (2007) 1.25
Association of the -173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol (2004) 1.25
Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer (2011) 1.24
Simple genotype analysis of the Asp299Gly polymorphism of the Toll-like receptor-4 gene that is associated with lipopolysaccharide hyporesponsiveness. J Clin Lab Anal (2002) 1.23
Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol (2007) 1.22
Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics (2005) 1.20
MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis (2011) 1.16
Identification of SCN3B as a novel p53-inducible proapoptotic gene. Oncogene (2004) 1.16
Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma. FEBS Lett (2003) 1.15
Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol (2004) 1.15
Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer (2009) 1.14
Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res (2009) 1.14
Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis. Clin Cancer Res (2004) 1.13
Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer (2002) 1.12
Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer (2006) 1.11
CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res (2007) 1.11
TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer (2010) 1.10
Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer. Cancer Lett (2002) 1.10
Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol (2004) 1.08
Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics (2003) 1.07
Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer Ther (2011) 1.07
Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol (2003) 1.06
Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. Clin Cancer Res (2008) 1.05
Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma. Mol Carcinog (2011) 1.04
Wnt antagonist gene polymorphisms and renal cancer. Cancer (2009) 1.04
Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene (2004) 1.04
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04
Integrin alpha2 mediates selective metastasis to the liver. Cancer Res (2009) 1.03
Sentinel lymph node biopsy using computed tomography-lymphography in patients with breast cancer. Surgery (2004) 1.03
Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer (2002) 1.02
Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clin Cancer Res (2008) 1.02
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn J Clin Oncol (2011) 1.00
Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics (2004) 1.00
Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett (2004) 1.00
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med (2014) 0.99
Impact of surgical site infection after colorectal surgery on hospital stay and medical expenditure in Japan. Surg Today (2012) 0.99
Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis (2005) 0.98
Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics (2006) 0.98
Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res (2002) 0.98
Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol (2009) 0.98
Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis. Oncogene (2003) 0.97
Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma. Carcinogenesis (2004) 0.97
IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma. Int J Cancer (2011) 0.97
Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer. J Urol (2008) 0.97
Upregulation of BNIP3 by 5-aza-2'-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J Gastroenterol (2005) 0.96
MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res (2005) 0.96
Breast sentinel lymph node mapping at CT lymphography with iopamidol: preliminary experience. Radiology (2003) 0.96
Lymphatic drainage from esophagogastric tract: feasibility of endoscopic CT lymphography for direct visualization of pathways. Radiology (2005) 0.96
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Res Notes (2012) 0.96
Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol (2005) 0.96
A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med (2014) 0.96
Role of secreted frizzled-related protein 3 in human renal cell carcinoma. Cancer Res (2010) 0.95
Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Biochem Biophys Res Commun (2006) 0.95
Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci (2009) 0.95
Predicting individual outcomes in hepatocellular carcinoma. Lancet (2004) 0.95
Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics (2010) 0.95
Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping: tetra-primer amplification refractory mutation system-polymerase chain reaction. Clin Chem Lab Med (2004) 0.94
CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer (2008) 0.94